Two groundbreaking treatments for metastatic melanoma are undergoing rapid adoption by oncologists, despite initial concerns over their high cost and the inclusion of a companion diagnostic for one of the drugs, according to a new survey. Yervoy (ipilimumab), Bristol-Myers Squibb Co.’s new melanoma treatment, had been prescribed by 79% of oncologists after six months on the market, and Roche’s Zelboraf (vemurafenib) had been prescribed by 58% of respondents six weeks post-launch, according to a survey...